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Letter to the editor
Burkholderia cepacia complex infection in adult
patients with cystic fibrosis—is early eradication
possible?
Sir,
Cystic Fibrosis (CF) is the commonest cause of
chronic lung disease in children and young adults, with
respiratory failure accounting for the majority of deaths.
Over the past two decades Burkholderia cepacia com-
plex wBccx has become a major respiratory pathogen in
CF. Transmissibility from person to person is well doc-
umented and patients with Bcc infection routinely attend
separate clinics and are admitted to a separate ward w1x.
The degree to which acquisition from the natural envi-
ronment contributes to infection is not clear.
Despite the relatively small proportion of patients
infected with Bcc (approx. 3–5% in most UK and USA
centres), it has had a major negative impact on mortality
and morbidity, associated with an increased risk of death,
an accelerated decline in pulmonary function and
increased hospitalisation w2x. FitzSimmons identified a
10-year reduction in the mean age of survival in the Bcc
population compared to individuals from whom only
Pseudomonas aeruginosa was cultured w3x.
The inherent high level of antibiotic resistance char-
acteristic of Bcc may reduce the efficacy of standard
antibiotic therapy. Although triple antibiotic combina-
tions containing tobramycin, meropenem and a third
additional antibiotic have been shown to be bactericidal
in 81–93% of isolates tested in vitro, the risk of drug
toxicity is high w4x.
One question that remains is whether the different
genomovars (gv) of Bcc have different antibiotic sus-
ceptibilities. Although intrinsic antibiotic resistance is
considered a common feature of Bcc, in vitro suscepti-
bility studies of 65 isolates from clinical and environ-
mental sources showed a wide variation in the MICs of
individual antimicrobials and resistance was not shown
by all members of the group w5x. It is also clear that
colonisation can be transient in some individuals w6x.
This is most likely to occur with the non-epidemic
strains which seem to be more sensitive on antibiotic
testing.
To date, nine different genomovars of Bcc have been
identified. Most CF isolates belong to gv II (Burkhold-
eria multivorans) and gv III (Burkholderia cenocepa-
cia). The latter is more transmissible, more likely to
cause chronic colonisation and associated with higher
rates of morbidity and mortality. Epidemic gv III strains
are associated with a 4-fold increase in mortality rates
w7x.
Since 1991, successful eradication regimens for early
Pseudomonas aeruginosa infection have been reported
w8x, now using 3 months nebulised colomycin and oral
ciprofloxacin w9x, 1 year nebulised tobramycin w10x or
nebulised tobramycin solution for inhalation (TOBI),
w11x. We present preliminary data on eradication therapy
for early Bcc infection.
Four patients were newly colonised with Bcc between
May and December of 2002. In each case the identifi-
cation was confirmed as Burkholderia multivorans using
molecular methods conducted by a recognised reference
laboratory (Laboratory of Hospital Infection, Central
Public Health Laboratory, Colindale, London). Patient 1
had just finished a 2 week course of intravenous anti-
pseudomonal therapy with tobramycin and meropenem
for a respiratory exacerbation at the time of confirmation
of B. multivorans infection. The isolate was sensitive to
all the routinely used anti-pseudomonal antibiotics
except for colistin. Nebulised TOBI was added to his
daily treatment regimen. The patient remained culture
negative for 6 months following this. Poor adherence to
nebulised therapy was documented prior to re-emergence
of B. multivorans in the sputum. The new growth was
treated with a further 2 weeks of intravenous antibiotic
therapy with amikacin and meropenem but sputum was
still culture positive at discharge.
B. multivorans was isolated from the remaining three
patients between November and December 2002. Sen-
sitivity testing of these isolates showed resistance only
to colistin, amikacin, tobramycin and cotrimoxazole. All
three patients received 2 weeks of triple intravenous anti-
biotic therapy with tobramycin, meropenem and cefta-
zidime and 3 months continuous nebulised TOBI. The
latter has been continued on alternate months in all three
patients. Following this intensive early therapy all three
patients have remained culture negative for B. multivor-
ans to date.
The antibiotic sensitivity findings of these B. multi-
vorans isolates differ to those usually recorded for gv III
isolates w5x. The latter are often pan-resistant and thus
attempts at eradication therapy may be less successful.
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We have shown initial successful eradication of B.
multivorans in all four patients. In the three patients
treated with a combination of triple intravenous and
nebulised antibiotic therapy sustained eradication to date
has been achieved with continued nebulised TOBI. The
high localised drug concentrations achieved with the
combination of intravenous tobramycin and nebulised
TOBI may be important w4x. We accept that transient
Bcc colonisation has been reported but believe these
results are still important.
Because of the significant negative impact of Bcc on
patient prognosis further evaluation of these and other
treatment combinations for early Bcc colonisation should
be explored. The response of different Bcc genomovars
to early therapy should also be evaluated.
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